Novo Nordisk Ends Hims Dispute, Expands Ozempic Sales while Lilly Pours $3B into China
Novo Nordisk dropped its lawsuit and agreed to let Hims & Hers sell branded Ozempic and Wegovy, adding a direct-to-patient channel for weight-loss drugs. Eli Lilly is investing $3 billion to expand GLP-1 manufacturing in China, targeting 141 million diabetics and 600 million obese adults and intensifying competition in its largest market.
1. Novo Nordisk and Hims & Hers Partnership
Novo Nordisk has dropped its lawsuit against Hims & Hers and sealed a deal allowing the telehealth provider to sell branded Ozempic and Wegovy. The agreement ends legal and marketing disputes, bars Hims from advertising compounded versions of the drugs and establishes a direct-to-patient distribution channel.
2. Eli Lilly’s $3 Billion China GLP-1 Investment
Eli Lilly has committed $3 billion to expand GLP-1 manufacturing capacity in China over the next decade. The investment targets 141 million diabetics and 600 million obese adults, intensifying competition for weight-loss and diabetes treatments in the world’s largest market.